Synergistic combination comprising roflumilast and a PDE-3 inhibitor
View Patent ↗The PDE 4 inhibitor N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxy benzamide, a pharmacologically tolerable salt or N-oxide thereof, in combination with a PDE 3 inhibitor is disclosed for use in inhibiting bronchospasms and treating acute obstructive bronchitis, asthma or COPD.
1. A commercial pharmaceutical product, consisting of a secondary pack that contains a primary pack containing the medicament and, optionally a pack insert, the medicament containing as active compound N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluorornethoxybenzamide, a pharmacologically tolerable salt or the N-oxide thereof, wherein in that on the secondary pack, and/or on the pack insert, is indicated that N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-ditluoromethoxybenzamide, a pharmacologically tolerable salt or the N-oxide thereof, is used in combination with a PDE3 inhibitor in the therapeutic treatment of disease conditions which are based on acute or chronic obstruction of vessels and/or bronchi and/or on acute or chronic inflammation.
2. A method of inhibiting bronchospasms in a patient comprising administering to said patient a combination of
a) N-(3, 5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or a pharmacologically tolerable salt or N-oxide thereof; and
b) a PDE3 inhibitor,
wherein said combination achieves a synergistic effect in the inhibition of bronchospasms.
3. The method of claim 2 , wherein said combination is a fixed combination for simultaneous administration.
4. The method of claim 2 , wherein the compounds a) N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or a pharmacologically tolerable salt or N-oxide thereof; and b) a PDE3 inhibitor are separated from each other and packaged in one unit for simultaneous or successive administration.
5. The method of claim 2 , wherein the PDE3 inhibitor is selected from the group consisting of ENOXIMONE, MILRINONE, MILRINONE lactate, and PIMOBENDAN.
6. A method of treating acute, obstructive bronchitis, extrinsic or intrinsic bronchial asthma, or COPD in a patient comprising administering to said patient a pharmaceutically effective amount of a pharmaceutical composition comprising N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or a pharmacologically tolerable salt or N-oxide thereof in combination with a PDE3 inhibitor.
7. The method of claim 6 , wherein said combination is a fixed combination for simultaneous administration.
8. The method of claim 6 , wherein the compound N-(3, 5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or a pharmacologically tolerable salt or N-oxide thereof and the FDE3 inhibitor are separated from each other and packaged in one unit for simultaneous or successive administration.
9. The method of claim 6 , wherein the PDE3 inhibitor is selected from the group consisting of ENOXIMONE, MILRINONE, MILRINONE lactate, and PIMOBENDAN.